BridgeBio Pharma, Inc. (BBIO) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 12.71B USD. 52-week range 52.75 to 93.42 USD. Data as of 2026-10-09.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; ...